Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy

Miyata, Yasuyoshi; Matsuo, Tomohiro; Nakamura, Yuichiro; Yasuda, Takuji; Ohba, Kenkichi; Takehara, Kosuke; Sakai, Hideki

doi:10.21873/anticanres.12394

Cited by 7 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Class III beta‐tubulin (TUBB3), which is one of beta‐tubulin isoforms has been reported to be associated with resistance to Taxol‐based chemotherapy. 26 , 27 Therefore, there is the possibility that we could predict response to paclitaxel by identifying such molecular marker in tumor tissues. Na et al showed that ATCs had higher expression of TUBB3.…”

Section: Discussionmentioning

confidence: 99%

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma

et al. 2022

View full text Add to dashboard Cite

The clinical utilities of paclitaxel in anaplastic thyroid carcinoma (ATC) have been reported. The current study investigated the outcomes in ATC patients treated by paclitaxel as neoadjuvant setting. Furthermore, the prognostic factor for overall survival (OS) and predictive marker for response to paclitaxel were investigated. Records of ATC patients treated by paclitaxel as neoadjuvant setting in our hospital were reviewed. The median OS for the patients with ( n = 43) and without ( n = 23) resection were 14.7 (95% CI, 11.0–21.7) and 4.2 (95% CI, 3.0–5.4) months, respectively ( p < 0.001). Univariate analysis identified the factors of stage ( p = 0.028), prognostic index (PI) ≥2 ( p < 0.001), response to paclitaxel ( p = 0.007), resection ( p < 0.001), and radiotherapy ( p < 0.001) to be associated with OS, and multivariate analysis revealed that the factors of PI ≥2 [hazard ratio (HR), 2.406 (95% CI, 1.096–5.281), p = 0.029], response to paclitaxel [HR, 0.423 (95% CI, 0.193–0.930), p = 0.032], resection [HR, 0.316 (95% CI, 0.129–0.773), p = 0.012], and radiotherapy [HR, 0.229 (95% CI, 0.100–0.526), p < 0.001] were independent prognostic factors of OS. There were no significant predictive factors for response to paclitaxel in baseline characteristics. PI ≥2, response to paclitaxel, resection, and radiotherapy were independent prognostic factors in ATC patients treated with paclitaxel as neoadjuvant setting. It is important to investigate predictor for response to paclitaxel for improving resectability and prognosis in ATC.

show abstract

Section: Discussionmentioning

confidence: 99%

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Resistance mechanisms for paclitaxel vary. It seems that several mutations in the TUBB gene are responsible for paclitaxel irresponsiveness most likely due to alterations of the binding site/binding pocket that diminish binding affinity, however, in addition to these mutations, it has been shown that just as in DNA-replication targeted therapies, high expression of β -tubulin also leads to low response rate 93 , 94 , 95 . Specific mutations in the TUBB gene such as A185T, A248V, R306C confer resistance to paclitaxel through naturally low microtubule stability 96 .…”

Section: Cytoskeleton-targetingmentioning

confidence: 99%

Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer

Jiang

Cai

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Non-small cell lung cancer is recognized as the deadliest cancer across the globe. In some areas, it is more common in women than even breast and cervical cancer. Its rise, vaulted by smoking habits and increasing air pollution, has garnered much attention and resource in the medical field. The first lung cancer treatments were developed more than half a century ago. Unfortunately, many of the earlier chemotherapies often did more harm than good, especially when they were used to treat genetically unsuitable patients. With the introduction of personalized medicine, physicians are increasingly aware of when, how, and in whom, to use certain anti-cancer agents. Drugs such as tyrosine kinase inhibitors, anaplastic lymphoma kinase inhibitors, and monoclonal antibodies possess limited utility because they target specific oncogenic mutations, but other drugs that target mechanisms universal to all cancers do not. In this review, we discuss many of these non-oncogene-targeting anti-cancer agents including DNA replication inhibitors ( i . e ., alkylating agents and topoisomerase inhibitors) and cytoskeletal function inhibitors to highlight their application in the setting of personalized medicine as well as their limitations and resistance factors.

show abstract

“…βII was also examined at the protein level in several cancer types, including head and neck carcinomas (LASCCHN), ovarian carcinoma, colorectal cancer, and breast cancer cell lines [194,196,198]. [200] NSCLC adenocarcinomas poor paclitaxel and eribulin [193] βII breast not determined docetaxel [196,201] [204] bladder, cisplatin resistant poor after paclitaxel chemotherapy n/a [205] gastric poor n/a [206] gastric metastatic poor after taxane chemotherapy n/a [207] uterine serous carcinoma poor paclitaxel, sensitivity to epothilone [208] lung carcinoma cell line n/a epothilone [ Similar to βI, in lung adenocarcinoma, breast cancer, and breast cancer cell lines, an increased level of βII was associated with resistance to MTA [191,196,201], while in LASCCHN, it was associated with poor survival after chemotherapy [198]. By contrast, in taxane-treated ovarian carcinomas, poor outcome is associated with a low level of βII [194].…”

Section: Tubulin Isotypes In Cancer and Anticancer Drug Resistancementioning

confidence: 99%

“…In a wide range of tumors and cancer cell lines, including small-cell lung carcinoma, NSCLC, ovarian, prostate, bladder, uterine, upper gastrointestinal, colon, pancreatic, LASCCHN, and gastric cancer, βIII upregulation is associated with the development of resistance to taxane-based chemotherapy and poor clinical outcome [ 121 , 200 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 210 , 211 , 212 , 213 , 215 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 ]. Moreover, an increased βIII level was also shown to be associated with EMT and cell motility of colon cancer cell lines [ 234 ].…”

Section: Factors Affecting Microtubule Dynamics In Cancer Cellsmentioning

confidence: 99%

Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells

et al. 2020

View full text Add to dashboard Cite

Microtubules (MTs), highly dynamic structures composed of α- and β-tubulin heterodimers, are involved in cell movement and intracellular traffic and are essential for cell division. Within the cell, MTs are not uniform as they can be composed of different tubulin isotypes that are post-translationally modified and interact with different microtubule-associated proteins (MAPs). These diverse intrinsic factors influence the dynamics of MTs. Extrinsic factors such as microtubule-targeting agents (MTAs) can also affect MT dynamics. MTAs can be divided into two main categories: microtubule-stabilizing agents (MSAs) and microtubule-destabilizing agents (MDAs). Thus, the MT skeleton is an important target for anticancer therapy. This review discusses factors that determine the microtubule dynamics in normal and cancer cells and describes microtubule–MTA interactions, highlighting the importance of tubulin isoform diversity and post-translational modifications in MTA responses and the consequences of such a phenomenon, including drug resistance development.

show abstract

Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy

Cited by 7 publications

References 26 publications

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma

Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer

Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells

Contact Info

Product

Resources

About